Granzyme B and perforin are cytoplasmic granule-associated proteins used by cytotoxic T lymphocytes and natural killer (NK) cells to kill their targets. However, granzyme B gene expression has also been detected in a non-cytotoxic hematopoietic murine multipotent stem cell line, FDCP-Mix. The objective of the present study was t o investigate whether granzyme B and perforin could be expressed in human hematopoietic CD34' cells and if present, discover what their physiologic relevance could be. The primitive CD34+ human cell line KGla was investigated first and was found t o express granzyme B and perforin. Highly purified hematopoietic stem/progenitor cells were then selected using the CD34 surface antigen as marker. Steady-state bone marrow (BM) CD34' cells did not contain these proteins. Peripheral blood (PB) CD34' cells, which had been induced t o circulate, were also analyzed. After chemotherapy (CT) and granulo-
ITHIN THE HEMATOPOIETIC system, the human CD34 surface antigen is selectively expressed on a population of stedprogenitor cells.'.' Growth and differentiation of CD34+ cells occur when there is a close contact between CD34+ cells and extracellular matrix proteins of the hematopoietic microenvironment.' Purified CD34' cells are capable of long-term hematopoietic reconstitution when reinfused in vivo after myeloablative therapy in animals4 or human^.^ Bone marrow (BM) CD34' cells can be induced to circulate by administration of hematopoietic growth factors (HGFs) or during the recovery phase after treatment with cytotoxic drugs. Strategies used for effective migration of BM CD34' to peripheral blood (PB) are of considerable interest as convenient harvesting of these cells in PB allows autologous and allogeneic transplantation to be performed. The most useful mobilizing techniques in clinical setting use either myelosuppressive chemotherapy (CT) and the subsequent administration of HGFs or treatment by HGFs [granulocyte macrophage colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF)].
The hematopoietic murine multipotent cell line, FDCPMix6 is likely to share similarities with CD34' cells. Hampson et a1 reported the presence of granzyme B mRNA in
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cyte colony-stimulating factor (G-CSF) treatment, CD34+ cells strongly expressed mRNAs and proteins of granzyme B and perforin. In contrast, CD34' cells mobilized by G-CSF alone were negative. Western blot analysis further showed that granzyme B and perforin proteins were identical in CD34+ cells and activated PBLs. Such proteins might be implicated in the highly efficient migration of CD34+ stem/progenitor cells from BM to PB after CT and G-CSF treatment. The cellular adhesion mechanisms involved in the BM homing of CD34+ cells are disrupted at least temporarily after CT. The Asp-ase proteolytic activity of granzyme B on extracellular matrix proteins could be used by progenitor cells for their rapid detachment from BM stromal cells and perforin might facilitate their migration across the endothelial cell barrier. 0 1995 by The American Society of Hematology.
this stem cell line.' In the present study, granzyme B and perforin expression was investigated in a human primitive CD34' hematopoietic cell line, KG1 a' and in human CD34' cells by in situ hybridization, immunohistochemistry, and Western blot analysis. Granzyme B and perforin are usually expressed in cytotoxic T lymphocytes and natural killer (NK) cells""' and constitute one of the pathways used by these cells to kill their targets.'"' The results indicated that granzyme B and perforin were present in KGla cells. The experiments performed on steady-state BM CD34' cells revealed that they did not contain the lytic proteins. Mobilization of CD34' cells under treatment by CT and G-CSF was associated with a strong granzyme B and perforin expression in all the patients tested. In contrast, G-CSF-mobilized PB CD34' cells never expressed these proteins. Western blot analysis further demonstrated that granzyme B and perforin proteins were identical in CD34' cells and activated T cells. Progenitor cells generated after CT-induced myelosuppression expressed the lytic proteins, but their physiologic function in the highly efficient migration of CD34' cells observed after treatment by CT and G-CSF remains to be determined.
MATERIALS AND METHODS
Preparation of BM suspensions. BM aspirates were obtained from the posterior iliac crest of two normal donors for allogeneic BM transplantation (BMT) and from two patients treated for acute lymphoblastic leukemia (ALL). CD34' cells from these patients were harvested during complete remission for autologous BMT (ABMT). The samples were immediately diluted I:1 with Iscove's modified Dulbecco's medium (IMDM; GIBCO Life Technologies, Cergy Pontoise, France) containing 20 UlmL of sodium heparin.
G-CSF mobilization protocol. G-CSF-mobilized PB cells were obtained from two normal volunteers after informed consent and from one person with chronic myelogenous leukemia. They received human recombinant G-CSF (Neupogen, Amgen, France) at a dose of 5 pgkg over 8 days, according to protocols already rep~rted.'~." Leukapheresis was performed on days 5 to 7 using Baxter CS3000 separators (Baxter, Irvine, CA).
Myelosuppressive CT with G-CSF mobilization protocol. Seven patients with non-Hodgkin's lymphoma (NHL) and one with my- Purijication of CD34+ cells. BM and apheresis samples were processed immediately after harvesting for CD34' selection using the immunomagnetic Baxter rneth~d.".'~ Briefly, BM and PB cells were centrifuged at low speed in order to remove platelets and were labeled with an anti-CD34 monoclonal antibody (MoAb) (Baxter) for 30 minutes at 4°C. After washes, cells were mixed with magnetic beads coated with sheep-antimouse IgG. Rosetted cells were separated by exposure to a magnetic field. Cells were released from the beads by chymopapain. The final CD34 purity of the cells was determined on a Becton Dickinson FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA) after cell staining with a phycoerythrin (PE)-labeled anti-CD34 MoAb. CD38 and HLA-DR antigen expression was also determined on purified CD34+ cells. Contamination of mature peripheral T cells in the enriched fraction was defined by fluorescein isothiwyanate (FITC)-labeled anti-CD2 and FITC anti-CD3 MoAbs. All MoAbs were obtained from Becton Dickinson Immunocytometry Systems. Cytospin slides of CD34' cells were prepared for in situ hybridization and immunohistochemical studies.
Cell lines. KGla cells and the monoblastic U937 cell line2" were cultured in RPM1 1640 (GIBCO, Paisley, Scotland) supplemented with 20% heat-inactivated fetal calf serum (FCS), 2 mmoYL glutamine, 10 mmoVL sodium pyruvate, 0.4% of penicillin streptomycin solution (GIBCO), and incubated in a humidified chamber at 37°C with 5% CO2 in air.
In situ hybridization study. The hybridization study was carried out on purified CD34+ cells from all patients mobilized by G-CSF alone, all patients harvested for allogeneic and autologous bone marrow transplantation and 6 patients undergoing CT and G-CSF mobilization. "S labeled RNA sense and anti-sense probes of granzyme B and perforin genes were prepared using T7 and SP6 RNA polymerase reactions, as described." In situ hybridization was performed according to the method described by Hoefler et al?' Sections hybridized with the labeled antisense probe (granzyme B, SP6 transcripts; perforin, T7 transcripts) were considered as positive for gene expression if they had at least three times the number of grains, compared with the cells with the highest background result. Phytohemagglutinin-interleukin-2 (PHA-E-2) treated PBLs were used as positive controls for granzyme B and perforin gene expression.
Immunohistochemical study. Immunohistochemical assays were performed on cells from all patients. Cytospin preparations were air dried and then fixed in acetone for 5 minutes. The slides were preincubated with human AB serum, and diluted at 30% in TBS (pH:7.6) for 5 minutes. After removal of AB serum, slides were incubated with the primary anti-CD34 MoAb (IgG; Becton-Dickinson), the antigranzyme B 18.1 (IgGl, antigranzyme B), or the antiperforin 6.4 (IgM, antiperforin) MOA^^'-^' for 30 minutes. Slides were then washed three times and detection of cell membrane and intracytoplasmic antigens was performed with the APAAP immunohistochemical technique.26
Western blot analysis.
Lysates of PB CD34+ cells (2 X lo6/ well), of PHA-IL2 activated PBLs (used as positive control), of U937 cells (used as negative control) were loaded on 12.5% or 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Gels were blotted onto a nitrocellulose membranes (BA83, CERA LABO) and blocked overnight with 5% nonfat milk PBS/ Tween 20 0.2%. The antihuman perforin MoAb (Perf-6.4) or the antihuman granzyme B MoAb (B 18.1) was added, respectively, at a 1/50 and 1/1 ,ooO final dilution for 1 hour, then washed and detected with a sheep-antimouse IgG peroxydase conjugate (V3,OOO final dilution for 1 hour). The membrane was dried on filter paper and developed with chemoluminescent peroxydase substrate (ECL, Amersham) for 1 minute according to the manufacturer's instructions.
RESULTS
KGla cell
line. The human primitive hematopoietic CD34' cell line KGla was investigated first for granzyme B and perforin expression. By in situ hybridization, these cells were found to express mRNAs of both proteins at a level of 50 grains per cell. All KGla cells were stained by the antigranzyme B and antiperforin MoAbs. Western blot analysis showed that granzyme B and perforin proteins were identical in KGla cells and in activated PBLs (data not shown).
CD34' Cells
Characterization. After the enrichment step, the purity of CD34+ cells was in the range of 85% IC_ 10%. The majority of CD34+ cells (96% ? 2%) was found to coexpress CD38 and HLA-DR antigens. The percentage of CD3+ T cells found in the purified CD34' cell fraction was in the range of 3% ? 2.5%.
In situ hybridization analysis. Granzyme B and perforin gene expression was investigated in highly enriched CD34' BM cells and in PB CD34' cells mobilized either by G-CSF alone or by CT followed by G-CSF. No signal was found when granzyme B and perforin sense controls were used. The CD34' cells purified from BM (two normal donors for allogeneic BMT and two ALL patients for ABMT) and apheresis after mobilization by G-CSF (two normal volunteers and one with CML) had no detectable level of granzyme B and perforin mRNAs. In contrast, 80% of PB CD34' cells mobilized by CT and G-CSF (five NHLs and one myeloma) strongly expressed mRNAs of granzyme B and perforin (75 2 20 grains per cell) (Fig l) .
Immunohistochemical analysis. To determine if granzyme B and perforin mRNA transcripts were further processed into proteins, CD34+ PB cells mobilized by CT and G-CSF from all patients were stained by antigranzyme B and antiperforin MoAbs. The subsequent results outlined that 80% k 20% of these cells expressed granzyme B and 93% ? 6% of them contained perforin (Fig 2) . Perforin and granzyme B expression was not found in steady-state BM CD34+ cells nor in G-CSF-mobilized CD34+ cells.
Western blot assay. Immunoblotting analysis was performed to characterize the molecular weight of granzyme B and perforin proteins present in PB CD34+ cells compared with that of activated PBLs. A 70-kD perforin protein was identified by immunoblotting cell lysates of CT and G-CSFmobilized CD34+ cells and PHA-activated PBLs (Fig 3) . In the same conditions, a 32-kD granzyme B protein was obtained with cell lysates of both activated PBLs and PB CD34' cells mobilized by CT and G-CSF (Fig 4) .
DISCUSSION
The perforin pathway represents one of the lytic mechanisms used by cytotoxic T lymphocytes and NK cells to kill their Perforin alone can be responsible for the This has been recently confirmed by the production of a granzyme B knockout mouse." The human granzyme B belongs to a cluster of hematopoietic serine protease genes including granzyme H, cathepsin G, and mast cell chymase, localized on the same chromosomal band as the human alb chains of the T-cell recept0r.j' This gene cluster is characterized by its tissue-restricted exprestoxic mature T cells, whereas cathepsin G is expressed during the promyelocyte/promonocyte stage of development and the mast cell chymase is only present in mast cells. However, CCP-I or granzyme B gene expression has been reported in a non-cytotoxic hematopoietic murine multipotent stem cell line, FDCP-Mix.' Therefore, the question was raised whether granzyme B and perforin could be detected in a human primitive hematopoietic CD34' cell line, named KGla. This study showed that KGla cells contained mRNAs and proteins of granzyme B and perforin. A further investigation was performed on human hematopoietic CD34' cells.
The CD34 antigen defines a heterogenous population composed of primitive hematopoietic stem cells with self-renewal capacity and of progenitors committed to myeloid, erythroid, and lymphoid devel~prnent.'~~" This antigen is expressed on I % to 4% of human BM cells.jx In this study, steady-state purified BM CD34+ cells were investigated first for granzyme B and perforin gene expression and they were found to be negative. Such a result might explain that granzyme B deficient mice had a normal hematopoiesis as reported by Heusel et al." The second approach concerned PB CD34' cells. Normal PB contains about 0.1% of CD34' cells.'9 After a short treatment by hematopoietic growth factors or during recovery of the hematopoietic system from cytotoxic-induced myelosuppression, about 4% of CD34' cells can be detected in PB.40 By in situ hybridization and immunohistochemistry, we showed that granzyme B and perforin mRNAs and proteins were expressed in human PB CD34' cells after treatment by CT and G-CSF. These data cannot be explained by peripheral contaminating CD3+ T cells, since highly enriched PB CD34+ cell populations were used. Furthermore, Western blot analysis showed that persion,'4.3s Granzyme B and H are detected in activated cytoforin and granzyme B proteins were identical in CD34' cells and activated PBLs. In contrast to the previous treatment including CT and G-CSF, the administration of G-CSF alone was unable to induce either granzyme B or perforin expression in CD34' cells. Granzyme B and perforin gene expression in human CD34' stedprogenitor cells contrasts with their previously described tissue-restricted distribution. However, the CD4 molecule, which is a functional T-cell-associated antigen, has recently been described on purified human BM CD34' cells?' The physiologic functions of granzyme B and perforin in cells other than mature T lymphocytes and NK cells are unknown. Granzyme B is a proteolytic protein with a highly unusual cleavage site preference for Asp residues."' Granzyme B expression, when induced in CD34' cells, could influence the proteolysis and function of an endogenously synthetized molecule, as recently demonstrated for an intracellular protease (the carboxypeptidase angiotensinconverting enzyme) directly involved in the processing of endogenous antigens presented to class I-restricted T lymp h o c y t e~.~~ Moreover, the natural substrate of the Asp-ase granzyme B could be RGD-containing adhesion molecules. One can hypothesize that perforin, the pore-forming p r~t e i n , '~.~* might facilitate the migration of hematopoietic stedprogenitor cells from BM to PB across the BM endothelial cell barrier.
It has to be noted that CD34' cells mobilized by CT alone were not available for analysis. Thus, it was not possible to determine whether induction of granzyme B and perforin expression in CD34' cells could be due only to CT-induced myelosuppression or required subsequent association with G-CSF. However, at least according to granzyme B and perforin expression, this study showed that CT and G-CSF- For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
